StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Free Report) in a research report sent to investors on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock.
Bellerophon Therapeutics Stock Performance
Shares of BLPH opened at $0.01 on Thursday. The business has a 50-day moving average of $0.03 and a 200 day moving average of $0.04. Bellerophon Therapeutics has a fifty-two week low of $0.01 and a fifty-two week high of $0.02. The firm has a market cap of $146,796.00, a P/E ratio of -0.01 and a beta of 0.74.
Bellerophon Therapeutics Dividend Announcement
The company also recently announced a dividend, which was paid on Wednesday, December 18th. Stockholders of record on Friday, December 20th were given a $0.019 dividend. This represents a dividend yield of 117.8%. The ex-dividend date was Thursday, December 19th.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
Featured Stories
- Five stocks we like better than Bellerophon Therapeutics
- What Do S&P 500 Stocks Tell Investors About the Market?
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
- Expert Stock Trading Psychology Tips
- Top 3 ETFs to Hedge Against Inflation in 2025
- Top Biotech Stocks: Exploring Innovation Opportunities
- These 3 Chip Stock Kings Are Still Buys for 2025
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
